Krishna Institute of Medical Sciences

    KIMS
    Pharma
    ₹759.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹31,878 Cr

    P/E
    145.40
    Day range
    ₹750.75 – ₹772.15
    52-week range
    ₹575.80 – ₹858.00
    Volume
    2.75 L
    Open
    ₹770.00
    Prev close
    ₹768.30

    Latest results · Q2 FY27(consolidated)Revenue ₹1,344 Cr+39.9%Profit ₹75 Cr+3.6%Margin 5.5%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter pledge went up

      11.71% of promoter shares pledged, up from 10.26% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 47 / 100

    Factor percentiles

    Value15
    Quality40
    Momentum57
    Low volatility78

    Derived metrics

    Earn. yield
    0.7%
    Graham no.
    ₹100.58
    vs Graham
    -86.7%
    ROE ÷ P/B
    1.4%
    12-1 mom.
    -2.2%
    Return / vol
    0.27
    Magic Formula
    #591
    Piotroski
    4/6
    FCF yield
    -2.9%
    PEG
    40.27

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Krishna Institute of Medical SciencesKIMS₹31,878 Cr145.408.1511.0%10.0%19.0%0.90+39.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2h ago

    Headlines about Krishna Institute of Medical Sciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    158.0
    Price / Book
    8.11
    ROE (FY26)
    11.0%
    ROCE (latest year)
    10%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹716.27
    Price above
    50-day
    ₹733.57
    Price above
    200-day
    ₹732.91
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +21.1%
    Profit 3Y CAGR
    -12.9%
    Revenue YoY (Sep 2026)
    +39.9%
    Profit YoY (Sep 2026)
    +4.2%
    Operating margin
    19.0%
    Net margin
    5.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • DII
    • Promoter
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-75%-50%-25%0%25%50%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    -2K Cr0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales6066346887777727978729619981,0751,1801,344
    Expenses4594755095595855996797577998689561,084
    Operating Profit147159179218187198193204199206223260
    OPM %24%25%26%28%24%25%22%21%20%19%19%19%
    Other Income3455181574511732
    Interest121618202627334557688366
    Depreciation35463941455353667985101121
    Profit before tax10210012716213513411497695557106
    Tax %25%28%25%26%31%21%25%26%24%40%34%29%
    Net Profit77729512192106857252333775
    EPS in Rs₹1.80₹1.64₹2.16₹2.68₹2.22₹2.54₹1.96₹1.67₹1.33₹1.06₹0.99₹1.79

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days52

    +22 days since Mar 2021

    Inventory Days37

    +7 days since Mar 2021

    Days Payable133

    -34 days since Mar 2021

    Cash Conversion Cycle52

    +158 days since Mar 2021

    Working Capital Days-37

    -6 days since Mar 2021

    Strengths, risks & growth

    Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.

    Strengths

    • Company is expected to give good quarter
    • Company's median sales growth is 21.9% of last 10 years

    Risks

    • Stock is trading at 8.15 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Promoter holding has decreased over last 3 years: -6.20%

    Compounded Sales Growth

    10 Years
    +23%
    5 Years
    +24%
    3 Years
    +21%
    TTM
    +35%

    Compounded Profit Growth

    10 Years
    +25%
    5 Years
    +4%
    3 Years
    -9%
    TTM
    -38%

    Stock Price CAGR

    10 Years
    —
    5 Years
    +25%
    3 Years
    +27%
    1 Year
    +13%

    Return on Equity

    10 Years
    +18%
    5 Years
    +18%
    3 Years
    +16%
    Last Year
    +11%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter34.11%34.11%32.49%32.65%+0.16 pp
    FII14.33%14.57%14.75%15.01%+0.26 pp
    DII32.72%32.50%34.42%33.22%-1.20 pp
    Public18.85%18.82%18.32%19.10%+0.78 pp

    Filed with NSE for Sept 2026: promoters 32.66%, public 67.34%

    Analysts & fund holdings

    100%
    100% recommend buy
    15 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E145.4 vs 45.2
    Sector P/B6.05
    Beta0.81

    Who holds the shares, quarter by quarter

    Mutual funds 28.21% (-0.31 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters32.7%
    • Foreign institutions15.0%
    • Mutual funds28.2%
    • Insurance4.1%
    • Other domestic institutions0.9%
    • Retail3.9%
    • Others15.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    SBI Small Cap Fund2.52%1.97%-0.25 pp
    HDFC Small Cap Fund2.44%2.01%-0.14 pp
    Axis Small Cap Fund2.08%2.28%-0.43 pp
    Kotak Small Cap Fund1.98%3.31%-0.28 pp
    Invesco India Smallcap Fund1.61%3.20%-0.91 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    30.8%
    Downside volatility
    29.0%
    Worst 5% of days
    3.2%
    Average of that tail
    4.0%
    Max drawdown (1Y)
    23.6%
    Below its peak
    10.8%

    Against the market

    Beta vs Nifty 50
    0.69
    Correlation
    0.31
    Relative strength (3M)
    -9.0%
    ATR (14)
    2.9%

    Return

    Return 1M
    +10.7%
    Return 3M
    -5.2%
    Return 6M
    +5.9%
    Return 1Y
    +8.3%
    vs 200-day average
    +3.6%

    Momentum

    RSI (14)
    63.3
    MACD histogram
    7.54
    Stochastic %K
    78.3
    ADX (14)
    26.3
    +DI / −DI
    26.9 / 12.1
    Money flow index
    47.6

    Participation

    Delivery (20d avg)
    58.0%
    vs its 60-day baseline
    +0.3 pts
    Volume vs 20-day
    -0.7σ
    Close vs day's VWAP
    +0.2%
    52-week position
    66 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    -₹917 Cr
    FCF yield
    -2.9%
    Cash conversion
    2.11
    Accruals ratio
    -0.035
    Net debt
    ₹3,486 Cr
    Net debt / equity
    0.89
    EV / sales
    7.69
    PEG
    40.27
    Capex intensity
    36.6%
    Revenue CAGR
    39.9%
    Profit CAGR
    3.6%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share

      13 Sept 2024
      ex-date

    Company announcements

    Company Update
    KIMS Swastha Private Limited ('KSPL'), Wholly-Owned Subsidiary Of The Krishna Institute Of Medical Sciences Limited ('Company') Has Entered Into An Operations And Management Agreement With LOVR Institute Of Medical Sciences Limited

    O & M Agreement

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Investor call held on 05.11.2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investec Pune Confluence

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Avendus Spark INDX: Annual Investor Conference

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio Call Link

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication for Q2FY27

    Company Update
    Deviation Report - QIP
    Company Update
    Deviation Report - Preferential Allotment
    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Preferential Allotment - Monitoring Agency Report

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    QIP - Monitoring Agency Report

    Company Update
    Announcement under Regulation 30 (LODR)-Scheme of Arrangement

    Intimation of Merger of Wholly owned subsidiary i.e KHPL with its holding company i.e Krishna Institute of Medical Sciences Limited

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Reappointment of Dr. Abhinay Bollineni, Dr. Bhaskara Rao Bollineni and Ms. Dandamudi Anitha

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor presentation

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Result
    Result For The Quarter Ended 30.09.2026

    Quarterly Result

    Filed with BSE (scrip 543308); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Krishna Institute of Medical Sciences: common questions

    Answered from the figures on this page.

    Krishna Institute of Medical Sciences last traded at ₹759.00 (NSE, as of 18 Nov 2026). The last session moved it down 1.21%.

    Krishna Institute of Medical Sciences is valued at about ₹31,878 crore (NSE, as of 18 Nov 2026).

    Krishna Institute of Medical Sciences trades at a price-to-earnings ratio of 145.40 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Krishna Institute of Medical Sciences has traded between ₹575.80 and ₹858.00 over the past 52 weeks, to 18 Nov 2026. It is currently 65% of the way up that range.

    Krishna Institute of Medical Sciences (KIMS) is classified under Pharma on this site's screener.